Galina Selivanova Group - Selected publications

Selected publications from the Galina Selivanova research group.

Recent publications

Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246.
Zhou X, Santos GS, Zhan Y, Oliveira MMS, Rezaei S, Singh M, Peuget S, Westerberg LS, Johnsen JI, Selivanova G.
Br J Cancer. 2022 Nov

Decreased DNA Damage and Improved p53 Specificity of RITA Analogs.
Zhan Y, Zhou X, Peuget S, Singh M, Peyser BD, Fan Z,Selivanova G.
Mol Cancer Ther. 2022 Oct

Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule.
Grinkevich VV, Vema A, Fawkner K, Issaeva N, Andreotti V, Dickinson ER, Hedström E, Spinnler C, Inga A, Larsson LG, Karlén A, Wilhelm M, Barran PE, Okorokov AL,Selivanova G, Zawacka-Pankau JE.
Front Mol Biosci. 2022 Jun 

Enterobacteria impair host p53 tumor suppressor activity through mRNA destabilization.
Aschtgen MS, Fragkoulis K, Sanz G, Normark S, Selivanova G, Henriques-Normark B, Peuget S
Oncogene 2022 Feb;():

p53-Dependent Repression: DREAM or Reality?
Peuget S, Selivanova G
Cancers (Basel) 2021 Sep;13(19):

Pharmacological activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting anti-tumor immunity.
Zhou X, Singh M, Sanz Santos G, Guerlavais V, Carvajal LA, Aivado M, Zhan Y, Oliveira MMS, Westerberg LS, Annis DA, Johnsen JI, Selivanova G
Cancer Discov 2021 Jul;():

Class IV Lasso Peptides Synergistically Induce Proliferation of Cancer Cells and Sensitize Them to Doxorubicin.
Guerrero-Garzón JF, Madland E, Zehl M, Singh M, Rezaei S, Aachmann FL, Courtade G, Urban E, Rückert C, Busche T, Kalinowski J, Cao YR, Jiang Y, Jiang CL, Selivanova G, Zotchev SB
iScience 2020 Dec;23(12):101785

Identification and targeting of selective vulnerability rendered by tamoxifen resistance.
Singh M, Zhou X, Chen X, Santos GS, Peuget S, Cheng Q, Rihani A, Arnér ESJ, Hartman J, Selivanova G
Breast Cancer Res 2020 07;22(1):80

p53 CRISPR Deletion Affects DNA Structure and Nuclear Architecture.
Rangel-Pozzo A, Booth S, Yu PLI, Singh M, Selivanova G, Mai S
J Clin Med 2020 Feb;9(2):

Thermal Proteome Profiling Identifies Oxidative-Dependent Inhibition of the Transcription of Major Oncogenes as a New Therapeutic Mechanism for Select Anticancer Compounds.
Peuget S, Zhu J, Sanz G, Singh M, Gaetani M, Chen X, Shi Y, Saei AA, Visnes T, Lindström MS, Rihani A, Moyano-Galceran L, Carlson JW, Hjerpe E, Joneborg U, Lehti K, Hartman J, Helleday T, Zubarev R, Selivanova G
Cancer Res 2020 04;80(7):1538-1550

Pifithrin-α alters p53 post-translational modifications pattern and differentially inhibits p53 target genes.
Zhu J, Singh M, Selivanova G, Peuget S
Sci Rep 2020 01;10(1):1049

RITA requires eIF2α-dependent modulation of mRNA translation for its anti-cancer activity.
Ristau J, van Hoef V, Peuget S, Zhu J, Guan BJ, Liang S, Hatzoglou M, Topisirovic I, Selivanova G, Larsson O
Cell Death Dis 2019 11;10(11):845

Inhibition of p53 inhibitors: progress, challenges and perspectives.
Sanz G, Singh M, Peuget S, Selivanova G
J Mol Cell Biol 2019 07;11(7):586-599

Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia.
Demir S, Boldrin E, Sun Q, Hampp S, Tausch E, Eckert C, Ebinger M, Handgretinger R, Kronnie GT, Wiesmüller L, Stilgenbauer S, Selivanova G, Debatin KM, Meyer LH
Haematologica 2020 01;105(1):170-181